{"filings":[{"id":2078636,"accession_number":"0001701541-26-000023","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2026-08-05T20:02:17+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics Q2 2026 net loss $9.9M; silevertinib shows 60% ORR in NSCLC","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and investments $110.5M as of June 30, 2026; runway into 2H 2028.","Net loss $9.9M vs $10.6M in Q2 2025; R&D expenses $7.4M, G&A $4.7M.","Phase 2 silevertinib in frontline non-classical EGFRm NSCLC: ORR 60%, CNS ORR 86%, median PFS 15.2 months.","No patients developed de novo brain metastases; 53% remain on therapy, longest 23.5 months.","FDA feedback on pivotal path for silevertinib in frontline NSCLC expected Q4 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1333718,"accession_number":"0001104659-26-078847","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2026-06-29T20:20:51+00:00","items":["5.07"],"status":"ready","headline":"BDTX annual meeting elects directors; Kapil Dhingra elected despite majority withheld votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shannon Campbell elected as Class III director with 19.3M for, 17.2M withheld; Kapil Dhingra elected with 14.0M for, 22.5M withheld.","Ratification of PwC as auditor approved: 44.4M for, 0.1M against, 0.2M abstain.","Advisory vote on executive compensation passed: 35.1M for, 1.2M against, 0.2M abstain, 8.2M broker non-votes.","Frequency of future say-on-pay set to annual (30.4M for 1-year); company will hold annual advisory votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":584316,"accession_number":"0001104659-26-065254","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2026-05-21T21:19:10+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond reports positive Phase 2 silevertinib results; mPFS 15.2 months in EGFR-NCM NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Preliminary mPFS 15.2 months (95% CI: 10.8, NE); median DOR not reached; 53% of patients remain on therapy.","CNS ORR 86%; no de novo brain metastases observed; 19 patients with brain metastases at baseline.","ORR 60%, DCR 91%; VAF reduction in all evaluable patients across 25 unique EGFR-NCMs including PACC.","No new safety signals; TRAEs > Grade 3 reduced to 28% after dose reduction; 150 mg QD selected for pivotal development.","Company plans to meet with FDA later this year to discuss pivotal development plan."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94805,"accession_number":"0001701541-26-000015","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics Q1 2026 net loss $9.0M; cash $118.3M; GBM trial dosed first patient","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $9.0M vs net income of $56.5M in Q1 2025 (prior year included license revenue).","Cash, cash equivalents, and investments $118.3M as of March 31, 2026; sufficient into 2H 2028.","R&D expenses $7.0M (down from $10.5M); G&A expenses $4.3M (down from $5.0M).","First patient dosed in Phase 2 trial of silevertinib + temozolomide for newly diagnosed EGFRvIII+ GBM.","Oral presentation of silevertinib Phase 2 frontline NSCLC data at ASCO 2026 on May 30."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.16,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107446,"accession_number":"0001701541-26-000008","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2026-03-16T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics FY2025: net income $22.4M; cash $128.7M; silevertinib milestones Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income of $22.4M for FY2025 vs net loss $69.7M in 2024; Q4 net loss $15.1M.","Cash, equivalents, investments $128.7M at Dec 31, 2025, funding operations into 2H 2028.","Silevertinib Phase 2 NSCLC update with preliminary DOR/PFS expected Q2 2026; randomized GBM trial to start Q2 2026.","R&D expenses $33.6M in FY2025, down 34% YoY due to restructuring and focus on silevertinib."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123789,"accession_number":"0001104659-25-117975","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-12-03T23:59:59+00:00","items":["2.02","7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond reports 60% ORR for silevertinib in 1L NSCLC; plans Phase 2 GBM trial; cash into 2H 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["60% ORR (26/43) in 1L NSCLC with 35 distinct non-classical EGFR mutations; 86% CNS ORR in patients with brain metastases.","No new safety signals; AEs managed with supportive care; 29/43 patients remain on therapy, longest >19 months.","Plans randomized Phase 2 trial of silevertinib+TMZ in ~150 ND GBM patients, initiated 1H 2026, preliminary data expected 2028.","Cash $135.5M as of Sep 30, 2025, now expected to fund operations into 2H 2028; partner assumed for NSCLC pivotal.","PFS and DOR data for NSCLC (recurrent and frontline) expected at medical meeting in Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123788,"accession_number":"0001701541-25-000038","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Q3 net loss $8.5M, cash $135.5M; silevertinib Phase 2 ORR data due Q4 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents and investments $135.5M as of Sept 30, 2025; funds operations into Q4 2027.","Net loss $8.5M in Q3 2025 vs $15.6M in Q3 2024; R&D expenses fell to $7.4M from $12.9M.","ORR and preliminary duration of treatment data from silevertinib Phase 2 in 1L non-classical EGFRm NSCLC expected later this quarter.","PFS data from Phase 2 trial expected in H1 2026; company plans FDA feedback on registrational path.","Exploring partnership opportunities for silevertinib in NSCLC and glioblastoma."],"consensus_eps_estimate":null,"consensus_eps_actual":0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":70000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140468,"accession_number":"0001701541-25-000029","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond completes Phase 2 enrollment for silevertinib; net loss narrows to $10.6M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $142.8M (vs $98.6M Dec 2024) funds operations into Q4 2027.","Net loss $10.6M in Q2 2025 vs $19.9M in Q2 2024; R&D expenses down to $9.3M.","Phase 2 trial of silevertinib in 1L non-classical EGFRm NSCLC fully enrolled (n=43); ORR & preliminary DOR data expected Q4 2025.","Exploring partnership opportunities for silevertinib in NSCLC and GBM; FDA meeting planned for 1H 2026 on registrational path."],"consensus_eps_estimate":null,"consensus_eps_actual":0.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":70000000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158155,"accession_number":"0001104659-25-058893","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Black Diamond Therapeutics elects three Class II directors, ratifies PwC","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class II directors elected: Behbahani (14.5M for, 20.0M withheld), Menzel (33.5M for, 0.96M withheld), Kulkarni (14.2M for, 20.3M withheld); 8.5M broker non-votes each.","Ratification of PwC as auditor for FY2025 passed: 42.48M for, 0.45M against, 59k abstain.","Annual meeting held June 12, 2025 with 42.99M shares present out of 56.68M outstanding, establishing quorum."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":158154,"accession_number":"0001701541-25-000021","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-05-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics Q1 net income $56.5M on Servier deal; cash runway into Q4 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net income $56.5M in Q1 2025 vs net loss $18.2M in Q1 2024, driven by $70M upfront from Servier licensing deal.","Cash, cash equivalents, and investments $152.4M as of March 31, 2025, up from $98.6M at Dec 31, 2024.","Guidance: cash sufficient to fund operations into Q4 2027.","Phase 2 data for BDTX-1535 in 1L NSCLC expected Q4 2025; FDA feedback on pivotal path planned.","Global licensing agreement with Servier for BDTX-4933 includes $70M upfront and up to $710M in milestones plus royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":0.98,"consensus_revenue_estimate":null,"consensus_revenue_actual":70000000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176519,"accession_number":"0001104659-25-025338","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Black Diamond grants Servier worldwide license for BDTX-4933; $70M upfront, up to $710M milestones","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $70M; eligible for up to $710M in development/commercial milestones plus tiered royalties on global sales.","Servier will lead global development and commercialization of BDTX-4933 in RAF/RAS-mutant solid tumors, including NSCLC.","BDTX-4933 is a Phase 1 small molecule designed to target RAS mutations and RAF alterations with best-in-class potential.","Black Diamond continues to advance its MasterKey platform; deal provides non-dilutive capital to support pipeline."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.78,"calibrated_materiality_score":0.78,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176518,"accession_number":"0001701541-25-000014","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2025-03-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics reports Q4/FY2024 net loss $16M/$69.7M; cash $98.6M into Q4 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, cash equivalents, and investments $98.6M at Dec 31, 2024, down from $131.4M at Dec 31, 2023.","Net loss for Q4 2024 was $16.0M, compared to $19.4M in Q4 2023; FY2024 net loss $69.7M vs $82.4M.","R&D expenses decreased to $12.3M in Q4 2024 from $15.3M in Q4 2023; FY2024 R&D $51.3M vs $59.4M.","Initial Phase 2 data for BDTX-1535 in newly diagnosed non-classical EGFRm NSCLC expected Q2 2025.","Cash runway expected into Q4 2026; management to seek FDA feedback on registrational path for BDTX-1535 in H2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193369,"accession_number":"0001701541-24-000040","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics reports Q3 net loss of $15.6M; BDTX-1535 Phase 2 data","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $15.6M in Q3 2024 vs $23.0M in Q3 2023; cash and investments $112.7M, sufficient into Q2 2026.","R&D expenses decreased to $12.9M from $16.2M YoY due to workforce efficiencies and reduced early discovery.","Announced restructuring in Oct 2024 to prioritize BDTX-1535 and extend cash runway; deprioritized BDTX-4933.","Initial Phase 2 data for BDTX-1535 in EGFRm NSCLC: 42% ORR in 19 patients with osimertinib resistance mutations; DOR ~8+ months in first 3 PRs.","Expects to disclose initial Phase 2 data in first-line and updated recurrent setting data plus FDA feedback in Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.99,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193368,"accession_number":"0001104659-24-106676","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond restructures to focus on BDTX-1535; CFO and CPO depart; cash runway extended to Q2 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["CFO Fang Ni and CPO Elizabeth Montgomery depart; Erika Jones appointed Principal Financial Officer.","Restructuring: reduction in force, deprioritize BDTX-4933 to seek partners, outsource CMC activities.","Cash runway extended into Q2 2026 due to restructuring cost savings.","BDTX-1535 Phase 2 data in frontline and recurrent EGFRm NSCLC expected Q1 2025 with potential registration path."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209715,"accession_number":"0001104659-24-101874","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-09-23T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond reports initial Phase 2 data for BDTX-1535 showing 42% ORR in recurrent EGFRm NSCLC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["200 mg daily dose selected for pivotal development; favorable tolerability with no new safety signals.","Preliminary ORR of 42% (8/19) in patients with C797S or PACC osimertinib-resistance mutations; 14/19 remain on therapy.","Duration of response ~8+ months for first 3 partial responders; mean follow-up 4.7 months.","Regulatory feedback on registration path expected Q1 2025; initial first-line data expected Q1 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209714,"accession_number":"0001701541-24-000028","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Q2 2024 net loss $19.9M; cash runway into Q4 2025; Phase 2 data on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, investments $123.0M at June 30, 2024, down from $131.4M at Dec 31, 2023; runway into Q4 2025.","Net loss $19.9M in Q2 2024 vs $19.2M in Q2 2023; R&D expenses decreased to $12.6M from $13.2M.","Initial Phase 2 data for BDTX-1535 in 2L/3L EGFRm NSCLC on track for later Q3 2024; 1L data in Q1 2025.","Initial Phase 1 data for BDTX-4933 in KRASm NSCLC on track for Q4 2024; ESMO poster in September 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.71,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227856,"accession_number":"0001104659-24-069070","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-06-06T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Black Diamond Therapeutics shareholders approve officer liability limitation and elect directors","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Shareholders approved Amendment to limit officer liability as permitted by Delaware law.","Prakash Raman and Mark A. Velleca elected as Class I directors to serve until 2027.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2024.","Certificate of Amendment filed and effective June 6, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227855,"accession_number":"0001701541-24-000020","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Q1 net loss $18.2M; cash $115.2M; Phase 2 BDTX-1535 data on track for Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $18.2M for Q1 2024 vs $20.9M in Q1 2023; R&D exp $13.5M, G&A $6.7M.","Cash, equivalents, investments $115.2M as of Mar 31, 2024; runway into Q3 2025.","Phase 2 BDTX-1535 in 2L/3L EGFRm NSCLC initial data expected Q3 2024; 1L cohort enrollment ongoing, data Q1 2025.","ASCO June 1: Phase 1 BDTX-1535 GBM dose-escalation and window-of-opportunity trial results.","Board changes: Shannon Campbell and Prakash Raman appointed; Wendy Dixon and Alex Mayweg stepped down."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.35,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227854,"accession_number":"0001104659-24-046096","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-04-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Black Diamond Therapeutics appoints Shannon Campbell and Prakash Raman to board; Dixon and Mayweg resign","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Wendy Dixon and Alex Mayweg resigned from board effective April 10, 2024; no disagreement cited.","Shannon Campbell (EVP/Chief Commercial Officer at Merus) appointed Class III director, will serve on Compensation Committee.","Prakash Raman (CEO of stealth biopharma) appointed Class I director, will serve on Audit and Nominating/Governance Committees.","New directors are independent under Nasdaq standards and will receive standard non-employee director compensation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246651,"accession_number":"0001701541-24-000009","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-03-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics reports Q4 2023 net loss of $19.4M, ends year with $131.4M cash","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss Q4 2023 $19.4M vs $21.1M in Q4 2022; full year net loss $82.4M vs $91.2M.","Cash, cash equivalents, investments $131.4M at Dec 31, 2023; expected to fund operations into Q2 2025.","Dosed first patient in Phase 2 trial of BDTX-1535 in 1L non-classical EGFRm NSCLC; Phase 2 data expected Q3 2024.","GBM results for BDTX-1535 in Q2 2024, initial results for BDTX-4933 in KRASm NSCLC in Q4 2024.","R&D expenses decreased to $59.4M for FY2023 from $64.4M in FY2022, primarily due to reduced early discovery spend."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246650,"accession_number":"0001104659-24-004802","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-01-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Board member Rajeev Shah resigns from Black Diamond Therapeutics board effective Jan 17, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rajeev Shah resigned from the Board and its Audit Committee, effective immediately on January 17, 2024.","Shah had served as a director since December 2018; resignation not due to any disagreement with the Company.","No replacement director has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246649,"accession_number":"0001104659-24-001155","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2024-01-04T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Black Diamond provides 2024 milestones: Phase 2 data for BDTX-1535 in NSCLC expected Q3; cash into Q2 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["FDA feedback enables Phase 2 first-line cohort for BDTX-1535 in non-classical EGFR mutant NSCLC; Fast Track granted for second-line C797S.","Phase 2 results for second/third-line EGFR mutant NSCLC expected Q3 2024; Phase 1 and window-of-opportunity GBM data expected Q2 2024.","Phase 1 results for BDTX-4933 in KRAS mutant NSCLC expected Q4 2024.","Existing cash, cash equivalents and investments expected to fund operations into Q2 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264073,"accession_number":"0001104659-23-125566","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2023-12-13T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond reports Phase 1 topline data for BDTX-1535 in recurrent GBM; durable stabilization seen","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["22 evaluable patients: 3 on therapy >10 months, 1 >6 months, 5 >4 months; historical PFS is 2–4 months.","19 measurable disease patients: 1 confirmed partial response (200 mg QD) and 8 stable disease per RANO criteria.","No new safety signals; AEs were Grade 1–2 diarrhea and rash, consistent with EGFR TKI class.","One patient remains on 100 mg QD for >15 months after progression on temozolomide at 3 months.","Company plans to present dose escalation results at a medical meeting in Q2 2024; window-of-opportunity trial enrolling."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":264072,"accession_number":"0001701541-23-000045","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics Q3 net loss $23.0M; cash $144.3M; advances BDTX-1535 and BDTX-4933 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $23.0M vs $21.7M in Q3 2022; R&D $16.2M, G&A $7.9M (includes CEO transition costs).","Cash, cash equivalents, and investments $144.3M at Sep 30, 2023; expected to fund operations into H1 2025.","BDTX-1535 Phase 1 expansion cohorts enrolling; initial NSCLC expansion data expected 2024; GBM dose escalation data later 2023.","BDTX-4933 Phase 1 trial dosed first patient; targeting KRAS, NRAS, BRAF mutations; dose escalation ongoing.","Mark Velleca appointed President and CEO in September 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.54,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281312,"accession_number":"0001104659-23-101377","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2023-09-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Black Diamond Therapeutics appoints Mark Velleca as CEO; David Epstein steps down","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David M. Epstein separated as President and CEO effective Sept 15, 2023; remains on board until 2024 annual meeting.","Mark Velleca, M.D., Ph.D. appointed President and CEO effective Sept 16, 2023; continues as Chairman.","Velleca receives $620K base salary, 55% target bonus, and stock options for 1,000,000 shares.","Samarth Kulkarni appointed Lead Independent Director; Audit/Nominating committees unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281311,"accession_number":"0001701541-23-000039","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics Q2 net loss $20M; cash $89.5M; BDTX-1535 shows initial clinical activity","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $20.0M for Q2 2023 vs $23.2M for Q2 2022; R&D expenses $13.2M down from $16.2M.","Cash, equivalents & investments $89.5M as of June 30, 2023; plus $75M gross from July follow-on offering extends runway into H1 2025.","BDTX-1535 Phase 1 dose-escalation showed confirmed partial responses in 5 of 12 evaluable NSCLC patients; expansion cohorts initiated July 2023.","Phase 1 trial for BDTX-4933 (BRAF/RAS inhibitor) initiated in Q2 2023; GBM dose-escalation update expected Q4 2023.","FDA meeting planned in Q4 2023 to discuss accelerated approval pathway for BDTX-1535 in NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300094,"accession_number":"0001104659-23-077061","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2023-06-30T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Black Diamond Therapeutics raises ~$71.6M in public offering of 15M shares at $5.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwritten public offering of 15,000,000 shares at $5.00/share; net proceeds ~$71.6M.","Underwriters have 30-day option to buy up to 2,250,000 additional shares (full exercise net ~$82.4M).","Proceeds to advance clinical pipeline including BDTX-1535 for non-small cell lung cancer and for working capital.","Underwriting agreement with Piper Sandler & Co.; officers/directors subject to 60-day lock-up.","Offering expected to close July 5, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300093,"accession_number":"0001104659-23-074995","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2023-06-27T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"BDTX-1535 shows 5/12 NSCLC patients with confirmed partial response; expansion cohorts planned","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["5 of 12 evaluable NSCLC patients achieved confirmed partial response per RECIST 1.1; 1 unconfirmed PR, 6 stable disease.","No dose-limiting toxicity at 15-200 mg QD; DLTs observed at 300 mg (1/15) and 400 mg (5/12).","Enrollment to start at 200 mg QD in two NSCLC expansion cohorts targeting acquired resistance and intrinsic driver mutations.","FDA meeting planned in H2 2023 to discuss dosing strategy and potential accelerated approval path.","Phase 1 GBM dose escalation update expected in Q4 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300092,"accession_number":"0001104659-23-061486","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Black Diamond Therapeutics elects three Class III directors, ratifies auditor at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["David M. Epstein, Wendy L. Dixon, and Kapil Dhingra elected as Class III directors to serve until 2026.","Epstein received 26.4M votes for, 84k withheld; Dixon 19.1M for, 7.3M withheld; Dhingra 20.0M for, 6.4M withheld.","PricewaterhouseCoopers LLP ratified as independent auditor for FY2023 with 31.0M for, 22k against, 18k abstain.","Meeting held virtually May 16, 2023; 31.1M shares represented out of 36.5M outstanding."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":300091,"accession_number":"0001701541-23-000030","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2023-05-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Q1 net loss $20.9M; cash $103.4M; BDTX-1535 update H2 2023; BDTX-4933 IND cleared","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $103.4M as of March 31, down from $122.8M at year-end 2022; net loss $20.9M vs $25.5M in Q1 2022.","Cash runway expected into Q3 2024.","Phase 1 dose escalation of BDTX-1535 ongoing; clinical update on track for H2 2023; dose-expansion cohorts to open in 2023.","FDA clearance for BDTX-4933 IND; first patient dosing expected in Q2 2023.","Development candidate BDTX-4876 (FGFR 2/3 selective) nominated; company evaluating strategic alternatives for FGFR program."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.57,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":320164,"accession_number":"0001701541-23-000018","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2023-03-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics reports Q4 net loss $21.1M; cash $122.8M; BDTX-1535 update H2 2023","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.1M in Q4 2022, full year net loss $91.2M (vs $125.6M in 2021).","Cash, cash equivalents and investments $122.8M as of Dec 31, 2022; sufficient into Q3 2024.","Phase 1 update for EGFR inhibitor BDTX-1535 expected H2 2023; trial actively recruiting.","FDA cleared IND for BRAF/RAS inhibitor BDTX-4933; Phase 1 start expected H1 2023.","Spinout of Launchpad Therapeutics with $30M Series A led by Versant and NEA; BDTX retains minority stake."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338311,"accession_number":"0001104659-22-128050","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-12-19T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Black Diamond Therapeutics changes Chairman; Robert Ingram resigns, Mark Velleca appointed","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Robert A. Ingram resigned as Chairman and Board member effective Dec 13, 2022; no disagreement with company.","Mark A. Velleca, M.D., Ph.D. appointed Chairman of the Board on Dec 15, 2022.","Board size reduced from 10 to 9 members upon Ingram's resignation.","Velleca has been a board member since Aug 2021, formerly CEO of G1 Therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338310,"accession_number":"0001104659-22-126074","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-12-12T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond Therapeutics spins out Launchpad Therapeutics with $30M Series A from Versant and NEA","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Spinout of Launchpad, an antibody-focused precision oncology company; $30M Series A led by Versant Ventures and NEA.","Black Diamond contributed undisclosed early-stage antibody programs and licensed its MAP Drug Discovery Engine to Launchpad.","Black Diamond received 9.0 million shares of Launchpad common stock (minority stake) for the contributed assets and license.","Black Diamond will continue focus on BDTX-1535, BDTX-4933, and small molecule pipeline while retaining upside via equity stake.","Launchpad will use the MAP Engine for large molecule discovery and development of novel antibody therapeutics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338309,"accession_number":"0001701541-22-000034","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Q3 2022 net loss $21.7M; cash $144.2M into Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.7M vs $35.1M YoY; R&D expenses fell to $15.8M from $27.6M.","Cash, equivalents & investments $144.2M at Sep 30, 2022, vs $209.8M Dec 31, 2021.","Net cash used in operations $16.5M for Q3 vs $26.5M a year ago; runway through Q3 2024.","BDTX-1535 clinical update expected in 2023; IND for BDTX-4933 planned H1 2023.","Appointed Melanie Morrison as SVP Development Operations in October 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355675,"accession_number":"0001701541-22-000028","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-08-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics Q2 2022 net loss $22.9M; cash $160.9M, runway into Q3 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $22.9M in Q2 2022, narrowing from $34.4M in Q2 2021.","Cash and investments $160.9M as of June 30, 2022; expected to fund ops into Q3 2024.","First patient dosed in Phase 1 study of BDTX-1535; clinical update expected in 2023.","Appointed Sergey Yurasov as Chief Medical Officer in June 2022.","IND submission for BDTX-4933 targeted for H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.33,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373926,"accession_number":"0001104659-22-069026","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-06-07T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Black Diamond Therapeutics announces 2022 annual meeting voting results","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Three Class II directors elected: Ali Behbahani (18.2M for), Garry Menzel (18.6M for), Samarth Kulkarni (21.8M for).","PricewaterhouseCoopers LLP ratified as auditor for FY2022 with 30.1M for, 14k against, 55k abstain.","Quorum of 30.2M shares out of 36.3M outstanding was present at the June 7, 2022 virtual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373925,"accession_number":"0001701541-22-000017","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics Q1 net loss $25.5M; cash runway into Q3 2024; BDTX-1535 phase 1 dosed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $25.5M vs $30.3M Q1 2021; R&D expense $17.8M (down from $22.8M).","Cash, equivalents, investments $179.7M; net cash used in ops $28.6M for Q1.","First patient dosed April 2022 in Phase 1 for BDTX-1535 (EGFR inhibitor, GBM/NSCLC); clinical update in 2023.","BDTX-4933 IND submission expected H1 2023; FGFR program candidate nomination in 2022.","Reduced workforce ~30% in April 2022; cash runway extended into Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373924,"accession_number":"0001104659-22-049317","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-04-25T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Black Diamond Therapeutics discontinues BDTX-189, cuts workforce 30% to extend cash runway into Q3 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued BDTX-189 due to rapid evolution of NSCLC treatment landscape (EGFR/HER2 Exon 20 insertions).","Reduced workforce by ~30% to increase operational efficiency and extend cash runway.","Cash runway extended into Q3 2024; $209M in cash, equivalents, and investments as of Dec 31, 2021.","Prioritized BDTX-1535 (Phase 1 for GBM/NSCLC) with clinical data update expected in 2023.","Prioritized BDTX-4933 (BRAF inhibitor); IND submission expected in first half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":373923,"accession_number":"0001104659-22-043424","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-04-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics appoints Wendy L. Dixon to board; Brad Bolzon resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brad Bolzon resigned from the Board effective April 5, 2022; not due to any disagreement with the company.","Wendy L. Dixon, Ph.D., appointed as Class III director effective April 6, 2022; deemed independent under Nasdaq rules.","Dr. Dixon brings over 40 years biopharma experience, including former CMO of Bristol Myers Squibb and board seats at Alkermes, Incyte, Arvinas.","She will receive standard non-employee director compensation and enter into an indemnification agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392565,"accession_number":"0001701541-22-000006","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-03-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics reports FY2021 net loss $125.6M; cash $209.8M, runway into 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss FY2021 $125.6M vs $67.3M YoY; Q4 loss $25.9M vs $22.6M.","Cash $209.8M at Dec 31, 2021 (down from $315.1M); sufficient to fund operations into 2024.","R&D spend $96.8M in 2021 (vs $48.2M); G&A $30.0M (vs $21.4M).","FDA allowed IND for BDTX-1535; Phase 1 study initiated for GBM and NSCLC with CNS metastases.","Appointed Elizabeth Montgomery as Chief People Officer, bringing nearly 20 years HR experience in life sciences."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392564,"accession_number":"0001104659-22-002587","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Black Diamond Therapeutics receives FDA IND clearance for BDTX-1535; Phase 1 start in Q1 2022","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["FDA allowed IND application for BDTX-1535 on January 10, 2022.","Phase 1 study of BDTX-1535 to begin in Q1 2022.","Company expects to provide a clinical update in the second half of 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":392563,"accession_number":"0001104659-22-002475","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2022-01-10T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Black Diamond submits IND for BDTX-1535 ahead of schedule; cash runway extended to 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["IND submitted for BDTX-1535 (CNS-penetrant EGFR inhibitor) for GBM and NSCLC; Phase 1 expected Q1 2022 subject to FDA allowance.","Company to enroll additional patients in BDTX-189 safety expansion; Phase 2 start gated pending further data.","Ended 2021 with ~$210M cash, sufficient to fund operations into 2024.","Anticipates IND-enabling studies for CNS-penetrant BRAF program in 2022.","Preclinical data shows BDTX-1535 activity in intracranial tumor models; targets ~50% of GBM patients."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410923,"accession_number":"0001104659-21-142198","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2021-11-22T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Black Diamond Therapeutics CFO Thomas Leggett resigns; Fang Ni named interim CFO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CFO Thomas Leggett resigned effective Nov 16, 2021, not due to any disagreement; will stay until Dec 3 for transition.","Board appointed Fang Ni, Pharm.D., Chief Business Officer, as Interim CFO and principal financial officer effective Nov 19.","Erika Jones, VP Finance and Corporate Controller, appointed principal accounting officer effective same date.","Ni's base salary $388,100, eligible for up to 40% annual bonus; severance includes lump sum equal to base salary.","Resignation and appointments are part of planned succession; no family relationships or conflicts reported."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":410922,"accession_number":"0001701541-21-000038","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2021-11-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics Q3 2021 cash $235M; BDTX-189 Phase 2 on track for year-end","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and investments $235.0M as of Sept 30, 2021; expected runway into H2 2023.","Net cash used in operations Q3 2021 was $26.5M, up from $11.5M in Q3 2020.","R&D expenses $27.6M (Q3 2021) vs $12.9M (Q3 2020), driven by headcount and preclinical/clinical costs.","BDTX-189 Phase 2 portion initiation by end of 2021; BDTX-1535 IND filing targeted H1 2022.","Preclinical data for BDTX-1535, BRAF, and FGFR programs presented at ANE conference; partnership with OpenEye Scientific."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.76,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429698,"accession_number":"0001701541-21-000032","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2021-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics reports Q2 2021 cash of $263.5M; pipeline advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash, equivalents, and investments $263.5M as of June 30, 2021; expected to fund operations into 2023.","R&D expenses $26.7M vs $10.2M in Q2 2020; net cash used in operations $49.6M.","BDTX-189 Phase 1 data presented at ASCO; Phase 2 initiation on track for H2 2021 after FDA dialogue.","IND filings planned: BDTX-1535 in H1 2022, BRAP and FGFR programs in 2022.","Appointed Elizabeth Buck as CSO, Karsten Witt as interim CMO; Drs. Humphrey and Roberts departed; Mark Velleca added to Board."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429697,"accession_number":"0001104659-21-102855","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2021-08-10T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Black Diamond Therapeutics appoints Mark Velleca to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Mark Velleca, M.D., Ph.D. as Class I director effective August 9, 2021.","Determined independent under Nasdaq listing standards; not appointed to any committees initially.","Will receive standard non-employee director compensation, including initial equity award per company policy.","Velleca brings over 20 years biotech experience; previously CEO of G1 Therapeutics (led from Series A to FDA approval).","No transactions with company requiring disclosure; selected per Board recommendation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":429696,"accession_number":"0001104659-21-100444","cik":1701541,"company_name":"Black Diamond Therapeutics, Inc.","ticker":"BDTX","form_type":"8-K","filed_at":"2021-08-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Black Diamond appoints interim CMO and new CSO; CMO and CSO depart","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Karsten Witt appointed Interim CMO, effective Aug 4, 2021, succeeding Rachel Humphrey.","Rachel Humphrey offered separation agreement with severance, advisory role until Feb 28, 2022; vested option extension.","Elizabeth Buck appointed Chief Scientific Officer, effective Aug 11, 2021, succeeding Christopher Roberts.","Christopher Roberts resigned to become CEO at another company; will serve as advisor post-departure."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":130075022.12554112,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}